SoftBank Group has teamed up with Chicago-based Tempus to form SB Tempus, a joint venture aimed at revolutionizing personalized medical services in Japan using AI-driven data analysis. The initiative will initially target oncology, the leading cause of death in Japan, with plans to expand to other medical fields. SoftBank’s $188 million investment underscores founder Masayoshi Son’s commitment to AI, a sector he believes will outsmart human intelligence significantly in the next decade. Tempus, known for its genomic testing and data analysis capabilities, plans to build clinical sequencing, organize patient data, and create real-world data businesses in Japan through SB Tempus. Despite Tempus’s fluctuating market valuation, this partnership aims to leverage AI to suggest personalized treatment plans, significantly enhancing the genomic testing landscape in Japan, where such testing is currently underutilized. This strategic move aligns with SoftBank’s broader AI ambitions, following a series of conservative investments and recent interest in Perplexity AI.
SoftBank and Tempus Form JV to Revolutionize Japan’s Cancer Treatment
SoftBank and Tempus join forces to bring AI-driven personalized cancer treatment to Japan.
1–2 minutes
TOP STORIES
Sanders’ proposal for a sovereign wealth fund aims to give the public a stake in AI companies, addressing issues of …
The White House’s ban on Anthropic’s AI models could reshape tech regulations …
Concerns about ASML’s EUV technology potentially reaching China could reshape global tech dynamics …
Google is partnering with Samsung to produce a new TPU, but TSMC remains crucial …
Attorneys can no longer claim ignorance of AI hallucinations as courts demand accountability …
Anthropic’s suspension of AI model access highlights India’s reliance on foreign technology and sparks discussions on developing domestic AI capabilities …
